Kornimate/medical-research-clean huggingface dataset:
vinegar-induced collection of duodenal pancreatic juice via endoscopic ultrasound

Conditions: Pancreatic Cancer

Summary: the goal of this clinical trial is to learn about the feasibility of collecting pancreatic juice through duodenal aspiration by ultrasound endoscopy (eus) for molecular marker testing after intraduodenal infusion of vinegar in patients with suspected pancreatic cancer and who are scheduled to have endoscopic ultrasound with fine needle aspiration (eus-fna). the main questions it aims to answer are: * is vinegar-induced collection of duodenal pancreatic juice via endoscopic ultrasound feasible? * what is the best operating condition (amount of vinegar, collection time, etc.) of vinegar-induced collection of duodenal pancreatic juice via endoscopic ultrasound? participants will have eus as scheduled, during which different amount of vinegar will be infused into duodenum and then pancreatic juice be collected for different time via suction by eus. researchers will compare the amount of collected pancreatic juice and molecular marker level in different groups to determine the best operating condition for vinegar-induced collection of duodenal pancreatic juice via endoscopic ultrasound.

this is a single center, prospective, randomized-controlled study. participants who are diagnosed as suspected pancreatic cancer and are schedule to have eus-fna will have saline or different amount of vinegar infused into duodenum and pancreatic juiced collected via eus suction during different period of time under intravenous anesthesia. the collected pancreatic juice will be weighed instantly and frozen in 10 minutes under -80℃ for further tests. researchers will compare the weight, cfdna (cell free dna) concentration, pla2g1b (phosphatidylcholine 2-acylhydrolase 1b) concentration, immunoglobulin concentration and kras (kirsten rat sarcoma viral oncogene) mutation load of collected pancreatic juice from different arms.

Eligibility criteria:
inclusion criteria: * age: 18 years old or older * diagnosis: ct, mri, transabdominal ultrasound or other imaging examinations showed a pancreatic mass, and 3 endoscopists agreed on the diagnosis of suspected pancreatic cancer * eus-fna is required to perform further treatment strategy * the patient can understand the study protocol, is willing to participate in the study and can provide written informed consent exclusion criteria: * the patient's clinical and imaging features do not support the diagnosis of suspected pancreatic cancer, judged by 3 endoscopists * the patient refuses to have eus-fna * the patient is unsuitable for eus-fna because of his/her general condition, or contraindicated for anesthesia * the patient's imaging suggests severe pancreatic duct obstruction * the patient cannot understand the conditions and objectives of this study, or refuse to participate in the study

Keywords: pancreatic cancer endoscopic ultrasound pancreatic juice
feasibility trial of a mediterranean diet pattern to prevent cognitive decline

Conditions: Alzheimer's Disease; Cognitive Impairment

Summary: by doing this study, researchers hope to learn if older adults with and without cognitive impairment can adhere to a mediterranean diet.

participants will be given instruction on following the study designed mediterranean diet. participation in the study will last about 9 weeks. each person will be asked to follow the study diet for 6 weeks. during the study, participants will be asked to track the food they eat and will be monitored by a registered dietitian. potential participants need to be located within the kc metro area.

Eligibility criteria:
inclusion criteria: * cognitively normal older adults over the age of 65 or individuals with a diagnosis of mci or ad (any age) * have a study partner, if diagnosed with mci or ad * body mass index (bmi) range between 20 - 35 kg/m2 * speak english as a primary language exclusion criteria: * serious medical risk * adherence to specialized diet regimes * already consume a mediterranean diet pattern
drug eluting balloon for prevention of constrictive remodeling

Conditions: Coronary Disease; Diabetes Mellitus

Summary: earlier studies indicated that percutaneous coronary intervention (pci) may be problematic in diffuse small vessel disease especially of diabetic patients. high restenosis rates after balloon only procedures in small vessels occur due to negative constrictive vessel remodeling if des (drug eluting stents) are not used and prolonged anti-platelet therapy is not indicated. the main hypothesis of the trial is that in analogy to dcb success in peripheral arterial disease (pad), cellular toxicity of the drug paclitaxel eluting from a in.pact falcontm dcb will prevent constrictive remodelling of small coronary vessel segments after dilatation. the in.pact falcontm dcb is compared with plain old balloon angioplasty (poba) using a sprinter legendtm balloon in small vessel coronary artery disease. a constrictive remodelling process will be measured by optical coherence tomography (oct) at 9 months median f/u. this pilot trial is planned to be randomized 1:1 for dcb against poba therapy.


Eligibility criteria:
inclusion criteria: * at least one target lesion with a stenosis severity ≥ 50% in one coronary segment with a diameter ≤ 2.5 mm * age \> 18 years * weight \> 45 kg * patient suitable for balloon dilatation and not suitable for elective implantation of a drug eluting stent * insulin-dependent or non-insulin-dependent diabetes mellitus * length of lesion ≥ 15 mm exclusion criteria: * life expectancy \< 12 months * in-stent restenosis * planned coronary bypass or heart valve op * st elevation myocardial infarction within the last 72 hours * cardiogenic shock * renal impairment or liver dysfunction (creatinine \> 2.0 mg/dl, ast/alt \> 3x of normal value * incompliance * pregnant or breastfeeding women or women who like to be pregnant

Keywords: drug eluting balloon constrictive remodeling
clinical measures of ovarian reserve in predicting ivf success

Conditions: Infertility, Female

Summary: the purpose of this study is to find out more about tests used to estimate the number of eggs a woman has remaining in her ovaries (her 'ovarian reserve'). it is thought that women who have a greater number of eggs or ovarian reserve may have a better chance of successful in vitro fertilisation (ivf) treatment than those who have a smaller number of eggs. accurately predicting the likely outcomes of ivf would be of great benefit for counselling patients before they go through expensive and demanding treatments such as ivf and ivf with intracytoplasmic sperm injection (ivficsi). over the past two decades, many endocrine and ultrasound markers have been designed and are now used as indicators of ovarian reserve. a number of screening tests are utilized to measure these markers, either by ultrasound scanning techniques or taking blood samples. however it is not yet known which, if any, best predict the outcome of ivf treatment. we would like to investigate these various measures of ovarian reserve to determine which are most accurate, particularly for predicting live birth rates, as up to now only poor to moderate quality evidence has been available for this outcome. this will be a prospective cohort study of 300 women who already intend to undergo ivf/ivf-icsi treatment. study participants will have one extra blood sample and ultrasound examination, for the purposes of measuring markers of their ovarian reserve, at the start of their ivf/ivficsi treatment cycle. no other interventions will be required and their treatment cycle will not be affected by their participation in the study.


Eligibility criteria:
inclusion criteria: * participant is willing and able to give informed consent for participation in the study. * female, aged 18 years or above. * first cycle of ovarian stimulation. * suitable for standard 'long protocol' ivf/ivf-icsi cycle. exclusion criteria: * the participant does not understand the english language, or has special communication needs. this is because it is impractical to provide, for this small scale study, information sheets and consent forms in other languages except english. * patients unsuitable for standard 'long protocol' ivf/ivficsi cycle * presence of endometrioma or any other kind of ovarian cyst \> 20mm diameter. * presence of polycystic ovarian syndrome.

Keywords: infertility assisted reproductive technology ovarian reserve
diafert for embryo selection and fertility improvement

Conditions: Infertility

Summary: prospective, single-center, single-blind, randomized, controlled, two-arm, interventional study.


Eligibility criteria:
inclusion criteria: * 1. women at least 18 years old at the time of informed consent. * 2. able to understand and voluntarily sign an informed consent form approved by the relevant independent ethics committee (iec) governing the site. * 3. first or second fresh assisted reproductive technology (art) cycle attempt (since last successful implantation, if any). * 4. eligible for elective set of fresh embryo on day 2/3. elective set is defined as a transfer for which there is more than one embryo in the same morphological ("best") category as that of the selected embryo. exclusion criteria: * 1. presence or history of ovarian endometriotic cyst. * 2. presence or history of diagnosed severe endometriosis (i.e. stage iv the revised american fertility society classification for endometriosis). * 3. hormonal, functional, anatomical and/or any other abnormalities potentially increasing the risk of miscarriage and/or ectopic pregnancy as judged by the investigator and determined by medical history and clinical laboratory. this includes, but is not limited to, uncontrolled diabetes mellitus, uncontrolled thyroid disease, alcoholism, drug abuse, abnormal uterine cavity etc. * 4. history of two or more consecutive miscarriages. * 5. known history of human immunodeficiency virus, hepatitis c virus and/or hepatitis b virus infection. * 6. the subject has other serious or acute conditions that, in the investigator's opinion, would preclude her participation in the study. * 7. need for preimplantation genetic diagnosis/screening. * 8. use of time-lapse embryo imaging. * 9. participating in oocyte donation procedure. * 10. participation in any interventional drug clinical investigation within 2 months prior to screening. * 11. dependency on sponsor or investigator (e.g. co-worker or family member).

Keywords: embryo transfer assisted reproductive technology
safety and immune response of covid-19 vaccination in overweight people with excessive bmi

Conditions: Covid19; Overweight

Summary: on 11 february 2020, the international committee for the classification of viruses named the disease caused by saｒs-cov-2 infection in humans as the new coronavirus pneumonia (coronavirus disease 2019, covid-19). due to the changes of immune function and cardiopulmonary function in overweight people, the infection and severity of these patients are higher than that of the general population during the epidemic period. more attention should be paid to personal protection and disease prevention. vaccination with covid-19 vaccine can effectively prevent covid-19 infection, delay or prevent patients from developing into critical illness and reducing mortality. in order to evaluate the safety and efficacy of covid-19 vaccine for overweight people, and to guide covid-19 vaccination more scientifically, rationally and effectively, this study was carried out.

due to the changes of immune function and cardiopulmonary function in overweight people, the infection and severity of these patients are higher than that of the general population during the epidemic period. more attention should be paid to personal protection and disease prevention. vaccination of covid-19 can effectively prevent covid-19 virus infection and delay or prevent patients from developing into critical illness and reduce mortality. the safety and effectiveness of covid-19 vaccine in this population were evaluated in order to play a scientific and theoretical supporting role in guiding covid-19 vaccination more scientifically, reasonably and effectively. the samples of this study were collected and tested in the second affiliated hospital of chongqing medical university. patients with contraindications for vaccination will be excluded. the detected indexes included blood routine test, liver function, covid-19 antibody titer, antibody duration and other indexes of healthy people (control group) and overweight people after vaccination ( 1, 3, 6 months after vaccination). the adverse reactions related to the vaccine were recorded.

Eligibility criteria:
inclusion criteria: - 1.healthy group were as follows: no history of hepatitis, no history of liver cirrhosis, no history of liver cancer and receiving the whole-course covid-19 vaccination. 2. overweight people are defined as having a bmi of more than 24 and receiving the whole-course covid-19 vaccination. exclusion criteria: * patients previously diagnosed or with a history of contact with confirmed cases

Keywords: covid-19
performance of pet 18 f-fdg coupled to ct with contrast injection iodized in the diagnosis of early recurrences of head and neck carcinoma treated with concurrent chemoradiation. comparison with 18f-fdg pet coupled with ct not injected with filling ct standard injection

Conditions: Squamous Cell Carcinoma of the Head and Neck

Summary: early detection of viable residual tumor or early neoplastic recurrence represents a real challenge in monitoring patients treated with concomitant chemoradiotherapy squamous cell carcinoma of the upper aerodigestive tract. the locoregional recurrence rate is indeed high (up 40%) over the first two years of this therapeutic method. the conventional imaging methods such as ct and mri appear limited in terms of sensitivity because of the many post-treatment changes are fibrosis, tissue edema and the tissue distortion. pet-ct 18f-fdg proves to be a non-invasive, reliable for the detection of residual tumor and metastasis, even in the absence of clinical signs. to date, the acquired ct examination in the same time and in the same position that pet is performed without iodinated contrast injection, used for anatomical identification and attenuation correction of pet fused images. the patient usually has a second ct imaging, centered on the neck with contrast injection iodized within the radiology department. to date, no team has yet studied the interest of the pet-ct 18f-fdg coupled with a ct scan with contrast injection iodized in the diagnosis of early recurrence in head and neck malignancies while interest of the contrast agent injection has been demonstrated in ovarian neoplastic recurrence research, pancreatic and colon.


Eligibility criteria:
inclusion criteria: * patients aged over 18 years * squamous cell carcinoma of head and neck * neoplastic location: oropharynx, oral cavity, hypopharynx, larynx * new patients treated with concomitant radiochemotherapy * treatment with chemoradiotherapy ended 3 months ago * affiliation to a social security scheme * patient who provided written informed consent exclusion criteria: * during pregnancy or absence of effective contraception in reproductive years * breastfeeding * creation of a cervical ct with injection of iodinated contrast, in the therapeutic monitoring, dated less than 14 days * other history of malignancy, including head and neck carcinomas previously treated outside the basal cell cancer or cervical cancer, treated and cured * uncontrolled infectious diseases * allergy to iodine * severe renal impairment (renal clearance \<30ml / min according to cockcroft) * no consent * patient deprived of liberty, under guardianship * any medical or psychological condition associated that might compromise the patient's ability to participate in the study * failure to submit to medical monitoring study for geographical, social or psychic
eras (enhanced recovery after surgery) protocol implementation in piedmont region for hysterectomy.

Conditions: Uterine Neoplasms

Summary: the study assesses the impact on quality of care of implementing the eras (enhanced recovery after surgery) protocol for hysterectomy of benign or malignant tumors of the uterus in the network of public hospitals in the regione piemonte (north-west italy). every hospital is a cluster entering the study treating patients according to its current clinical practice. on the basis of a randomized order, each hospital switches from current clinical practice to the adoption of the eras protocol.

eras (enhanced recovery after surgery) protocol is a multimodal perioperative care pathways designed to achieve early recovery after surgical procedures by maintaining preoperative organ function and reducing the profound stress response following surgery. even if efficacy and safety of eras protocol in gynaecological surgery is well-established in the literature, its implementation is limited to few selected centres in piemonte. the aim of the study is to extend the implementation of the eras protocol to whole regional network of hospitals. specific objectives are to estimate its impact on different dimensions of quality of care, including length of stay, complications and patient satisfaction, and to identify possible barriers or facilitating factors.

Eligibility criteria:
inclusion criteria: * all the hospital wards within the piemonte region performing hysterectomy. * all the patients receiving an elective hysterectomy for benign or malignant tumors of the uterus. exclusion criteria: * hospital wards performing less than 20 expected cases per year * emergency hysterectomy * hysterectomy for pelvic floor disorders * high severity cases not allowing eras protocol implementation (i.e. american society of anesthesiologists score: asa v).

Keywords: hysterectomy uterine cervical neoplasms endometrial neoplasms quality improvement perioperative care recovery of function
finhyst 2006: study on morbidity of hysterectomies in finland

Conditions: Morbidity of Hysterectomy

Summary: the purpose of this study is to analyze prospectively all hysterectomies performed in finland for benign indications including all 46 public hospitals performing hysterectomies and also 7 private clinics. hypothesis is that vaginal and laparoscopic hysterectomies are safe and cost-effective methods of hysterectomy.

this finhyst 2006 study evaluates nationwidely methods, indications, concomitant procedures, complications, hospital stay and convalescence time of all types of hysterectomies with questionnaires filled by doctors and patients. in addition, in the area of helsinki university central hospital also the effect of quality of life and cost-effectiveness is studied.

Eligibility criteria:
inclusion criteria: * bening indications for hysterectomy exclusion criteria: * malignant indications for hysterectomy * postpartum hysterectomy

Keywords: hysterectomy vaginal laparoscopy abdominal complication quality of life cost-effectiveness morbidity of three types of hysterectomy
cuff-assisted colonoscopy vs standard colonoscopy

Conditions: Colonic Polyp; Colonoscopy

Summary: the goal of this study is to evaluate the interest of second-generation endocuff vision (ecv) to improve adenoma detection rate and / or polyp detection rate in routine colonoscopy. this is a prospective comparative cohort, on 1034 patients, 517 patients with ecv in prospective group and 517 without ecv in retrospective group


Eligibility criteria:
inclusion criteria: * patient scheduled for total colonoscopic exploration, during the period study * patient over or equal to 18 years * asa 1, asa 2, asa 3 * no participation in another clinical study * certificate of non opposition signed exclusion criteria: * patient under 18 years old * asa 4, asa 5 * pregnant woman * patient with coagulation abnormalities preventing polypectomy: prothrombin level \<50%, -platelets \<50000 / mm3, effective anti-coagulation in progress, clopidogrel in progress. * inflammatory bowel disease * known colonic stenosis * diverticulitis less than 6 weeks old * patient unable to give consent or protected by law * opposition expressed for inclusion in the study
statin adjunct therapy among art-treated adults in sub-saharan africa: atorvastatin and rosuvastatin equivalence trial

Conditions: HIV Infection

Summary: this study will determine whether 36 months of daily atorvastatin or rosuvastatin have equivalent effects in reduction of immune activation, inflammation and immune aging, when given as adjunct therapy among patients receiving antiretroviral therapy in an african cohort

this is a randomized, open-label trial

Eligibility criteria:
inclusion criteria: * hiv-positive individuals 18 years and older, that have initiated three first-line drug highly active antiretroviral therapy within three months within the infectious diseases institute hiv treatment cohort * individuals that provide written informed consent to participate in the clinical trial exclusion criteria: individuals with dyslipidemia and eligible to receive or already receiving statin therapy * pregnant or lactating mothers * individuals with another active or controlled inflammatory condition * individuals with deranged liver function tests 3 fold and above

Keywords: adults antiretroviral therapy
validity and feasibility of the crsr-fast

Conditions: Disorder of Consciousness; Traumatic Brain Injury

Summary: the crs-r is a standardized and validated bedside assessment of conscious awareness. it is used routinely for diagnosis and prognosis of patients with disorders of consciousness (doc) as well as in research settings. one limitation of the crs-r is the lengthy administration time required to obtain a total score. administration time can vary from approximately 15-30 minutes, depending on the patient's level of responsiveness. for this reason, the crs-r is rarely administered in the acute hospital setting. less time-consuming scales and metrics are used to assess conscious awareness in the acute hospital/icu setting, but they lack specificity and sensitivity and have not been validated, increasing the potential for misdiagnosis. we have developed the crsr-fast and aim to test its validity, inter- and intra- rater reliability. we anticipate that, compared with the crs-r, the crsr-fast will be less time-consuming to administer and score, but will maintain a high level of sensitivity to detecting signs of consciousness in severely brain injured patients.


Eligibility criteria:
inclusion criteria: * age 18 or older * fluent in english * surrogate available to provide informed consent * history of severe acquired brain injury * sustained a traumatic brain injury (tbi, defined by damage to brain tissue caused by an external mechanical force), * be within 3 weeks of injury * have a total glasgow outcome scale (gcs) score \<9 within the first 48 hours of injury, * be unable to follow simple commands consistently at the time of enrollment exclusion criteria: * history of developmental, neurologic, or major psychiatric disorder resulting in ongoing functional disability up to the time of the current injury * physician orders for comfort measures only
emergency department (ed) triage of alcohol abuse

Conditions: Alcoholic Intoxication

Summary: retrospective study of adult patients (\> 16 y) admitted to geneva university hospitals with alcohol abuse. triage criteria will be reviewed. patients characteristics and patient flow in the ed will be described.

a retrospective analysis of triage notes and electronic medical records will be performed in order to identify how triage evaluation is performed accordingly to the swiss emergency triage scale criteria. the proportion of patients leaving without being seen will be computed. caracteristics of these patients will be compared to patients with medical evaluation.

Eligibility criteria:
inclusion criteria: * triage code = alcohol abuse * \> 16 y exclusion criteria: * no alcohol abuse identified at triage * \< 16 y

Keywords: n04.452.442.422.336